2. Elevated urinary organic acids: phenylpropionylglycine, suberylglycine, hexanoylglycine, and medium chain dicarboxylic acids (C6>C8>C10).
3. Molecular genetic studies confirming the presence of the 985 A>G mutation, or other less common mutations.
4. Skin fibroblasts acylcarnitine probe assay demonstrating accumulation of characteristic acylcarnitines.
Skin fibroblasts enzyme studies showing reduced activity of MCAD.
In the presence of the following clinical features or biochemical findings: 
